enetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels. The absence of oral and affordable anti-PCSK9 medications has limited the beneficial effects of this new therapeutic option. A possible breakthrough in this field may come from the discovery of new naturally occurring PCSK9 inhibitors as a starting point for the development of oral, small molecules, to be used in combination with statins in order to increase the percentage of patients reaching their LDL-cholesterol target levels. In the present review, we have summarized the current knowledge on natural compounds or extracts that have shown an inhibitory effect on PCSK9, either in experimental or clinical settings. When available, the pharmacodynamic and pharmacokinetic profiles of the listed compounds are described.
Naturally Occurring PCSK9 Inhibitors / Adorni, Maria Pia; Zimetti, Francesca; Giovanna Lupo, Maria; Ruscica, Massimiliano; Ferri, Nicola. - In: NUTRIENTS. - ISSN 2072-6643. - 12:5(2020), p. 1440. [10.3390/nu12051440]
|Appare nelle tipologie:||1.1 Articolo su rivista|